{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:25:53Z","timestamp":1778552753337,"version":"3.51.4"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1097\/cco.0b013e328351c646","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T13:55:16Z","timestamp":1329400516000},"page":"284-290","source":"Crossref","is-referenced-by-count":43,"title":["Targeted therapeutic strategies for the management of renal cell carcinoma"],"prefix":"10.1097","volume":"24","author":[{"given":"Eric A.","family":"Singer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopal N.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramaprasad","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-15-20210128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics.","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R2-15-20210128","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3322\/caac.20121","article-title":"Cancer statistics 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.","volume":"61","author":"Siegel","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R4-15-20210128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11523-010-0148-3","article-title":"Targeted therapies for nonclear renal cell carcinoma.","volume":"5","author":"Singer","year":"2010","journal-title":"Target Oncol"},{"key":"R5-15-20210128","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/CCO.0b013e32834479c0","article-title":"Update on targeted therapies for clear cell renal cell carcinoma.","volume":"23","author":"Singer","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"R7-15-20210128","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMra043172","article-title":"Renal-cell carcinoma.","volume":"353","author":"Cohen","year":"2005","journal-title":"N Engl J Med"},{"key":"R8-15-20210128","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von hippel-lindau disease tumor suppressor gene.","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"key":"R9-15-20210128","doi-asserted-by":"crossref","first-page":"e1002312","DOI":"10.1371\/journal.pgen.1002312","article-title":"Von hippel-lindau (vhl) inactivation in sporadic clear cell renal cancer: associations with germline vhl polymorphisms and etiologic risk factors.","volume":"7","author":"Moore","year":"2011","journal-title":"PLoS Genet"},{"key":"R10-15-20210128","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature09639","article-title":"Exome sequencing identifies frequent mutation of the swisnf complex gene pbrm1 in renal carcinoma.","volume":"469","author":"Varela","year":"2011","journal-title":"Nature"},{"key":"R11-15-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"R12-15-20210128","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"R13-15-20210128","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (avoren): final analysis of overall survival.","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"key":"R14-15-20210128","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase iii trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of calgb 90206.","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"key":"R15-15-20210128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma.","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"R16-15-20210128","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors.","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"R17-15-20210128","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"R18-15-20210128","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"R19-15-20210128","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (axis): a randomised phase 3 trial.","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"R20-15-20210128","first-page":"191","article-title":"Development and validation of the functional assessment of cancer therapy-kidney symptom index (fksi).","volume":"4","author":"Cella","year":"2006","journal-title":"J Support Oncol"},{"key":"R21-15-20210128","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1524-4733.2007.00183.x","article-title":"Development and validation of a scale to measure disease-related symptoms of kidney cancer.","volume":"10","author":"Cella","year":"2007","journal-title":"Value Health"},{"key":"R22-15-20210128","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the met proto-oncogene in papillary renal carcinomas.","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet"},{"key":"R23-15-20210128","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1158\/1078-0432.CCR-06-0818","article-title":"Targeting the c-met signaling pathway in cancer.","volume":"12","author":"Peruzzi","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R24-15-20210128","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1464-410X.2010.09947.x","article-title":"A phase II study of the efficacy and safety of amg 102 in patients with metastatic renal cell carcinoma.","volume":"108","author":"Schoffski","year":"2011","journal-title":"BJU Int"},{"key":"R25-15-20210128","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1200\/jco.2008.26.15_suppl.5103","article-title":"A phase II study of the dual metvegfr2 inhibitor xl880 in patients (pts) with papillary renal carcinoma (prc).","volume":"26","author":"Srinivasan","year":"2008","journal-title":"J Clin Oncol"},{"key":"R26-15-20210128","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1200\/jco.2009.27.15_suppl.5103","article-title":"A phase II study of two dosing regimens of gsk 1363089 (gsk089), a dual metvegfr2 inhibitor, in patients (pts) with papillary renal carcinoma (prc).","volume":"27","author":"Srinivasan","year":"2009","journal-title":"J Clin Oncol"},{"key":"R27-15-20210128","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12032-009-9177-0","article-title":"Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.","volume":"26","author":"Dutcher","year":"2009","journal-title":"Med Oncol"},{"key":"R28-15-20210128","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.urology.2006.09.052","article-title":"Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification.","volume":"69","author":"Pignot","year":"2007","journal-title":"Urology"},{"key":"R29-15-20210128","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","article-title":"Hif overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of hif stability.","volume":"8","author":"Isaacs","year":"2005","journal-title":"Cancer Cell"},{"key":"R30-15-20210128","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1128\/MCB.00483-09","article-title":"Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species.","volume":"29","author":"Sudarshan","year":"2009","journal-title":"Mol Cell Biol"},{"key":"R31-15-20210128","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ccr.2011.07.018","article-title":"The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers ampk levels, increases anabolic propensities and lowers cellular iron levels.","volume":"20","author":"Tong","year":"2011","journal-title":"Cancer Cell"},{"key":"R34-15-20210128","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9440(10)61684-7","article-title":"Primary renal neoplasms with the aspl-tfe3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.","volume":"159","author":"Argani","year":"2001","journal-title":"Am J Pathol"},{"key":"R35-15-20210128","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0002-9440(10)64680-9","article-title":"A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal hmb45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation.","volume":"158","author":"Argani","year":"2001","journal-title":"Am J Pathol"},{"key":"R36-15-20210128","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/00313021003767348","article-title":"Xp11 translocation renal cell carcinoma.","volume":"42","author":"Ross","year":"2010","journal-title":"Pathology"},{"key":"R37-15-20210128","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.juro.2010.08.092","article-title":"Transcription factor e3 and transcription factor eb renal cell carcinomas: clinical features, biological behavior and prognostic factors.","volume":"185","author":"Malouf","year":"2011","journal-title":"J Urol"},{"key":"R38-15-20210128","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1101\/gad.12.19.3084","article-title":"Synergistic cooperation of tfe3 and smad proteins in tgf-beta-induced transcription of the plasminogen activator inhibitor-1 gene.","volume":"12","author":"Hua","year":"1998","journal-title":"Genes Dev"},{"key":"R39-15-20210128","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/PAS.0b013e3181e8ce5b","article-title":"Xp11 translocation renal cell carcinoma (rcc): extended immunohistochemical profile emphasizing novel rcc markers.","volume":"34","author":"Argani","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R40-15-20210128","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1158\/0008-5472.CAN-06-2855","article-title":"Tfe3 fusions activate met signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic met inhibition.","volume":"67","author":"Tsuda","year":"2007","journal-title":"Cancer Res"},{"key":"R41-15-20210128","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1002\/cncr.25512","article-title":"Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic xp11.2 translocation renal cell carcinoma.","volume":"116","author":"Choueiri","year":"2010","journal-title":"Cancer"},{"key":"R42-15-20210128","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/annonc\/mdq029","article-title":"Targeted agents in metastatic xp11translocationtfe3 gene fusion renal cell carcinoma (rcc): a report from the juvenile rcc network.","volume":"21","author":"Malouf","year":"2010","journal-title":"Ann Oncol"},{"key":"R44-15-20210128","first-page":"356","article-title":"Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization.","volume":"145","author":"Speicher","year":"1994","journal-title":"Am J Pathol"},{"key":"R45-15-20210128","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1471-2407-10-196","article-title":"Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma.","volume":"10","author":"Tan","year":"2010","journal-title":"BMC Cancer"},{"key":"R46-15-20210128","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1309\/A7M2XTMJQK0KPQER","article-title":"Overexpression of kit (cd117) in chromophobe renal cell carcinoma and renal oncocytoma.","volume":"121","author":"Pan","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"R47-15-20210128","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1097\/01.ju.0000154629.45832.30","article-title":"3rd, Hurley K, et al. Evaluation and management of renal tumors in the birt-hogg-dube syndrome.","volume":"173","author":"Pavlovich","year":"2005","journal-title":"J Urol"},{"key":"R48-15-20210128","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1086\/323744","article-title":"Birt-hogg-dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2.","volume":"69","author":"Schmidt","year":"2001","journal-title":"Am J Hum Genet"},{"key":"R49-15-20210128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1535-6108(02)00104-6","article-title":"Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the birt-hogg-dube syndrome.","volume":"2","author":"Nickerson","year":"2002","journal-title":"Cancer Cell"},{"key":"R50-15-20210128","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/jnci\/djm288","article-title":"Kidney-targeted birt-hogg-dube gene inactivation in a mouse model: erk12 and akt-mtor activation, cell hyperproliferation, and polycystic kidneys.","volume":"100","author":"Baba","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R51-15-20210128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2007.13.3223","article-title":"Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.","volume":"26","author":"Choueiri","year":"2008","journal-title":"J Clin Oncol"},{"key":"R52-15-20210128","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/jnci\/djn254","article-title":"Germline sdhb mutations and familial renal cell carcinoma.","volume":"100","author":"Ricketts","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R53-15-20210128","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/hmg\/ddi227","article-title":"Accumulation of krebs cycle intermediates and over-expression of hif1alpha in tumours which result from germline fh and sdh mutations.","volume":"14","author":"Pollard","year":"2005","journal-title":"Hum Mol Genet"},{"key":"R54-15-20210128","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis.","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"R55-15-20210128","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrurol.2010.47","article-title":"The genetic basis of kidney cancer: a metabolic disease.","volume":"7","author":"Linehan","year":"2010","journal-title":"Nat Rev Urol"},{"key":"R56-15-20210128","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex.","volume":"355","author":"Crino","year":"2006","journal-title":"N Engl J Med"},{"key":"R57-15-20210128","first-page":"1201","article-title":"Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features.","volume":"149","author":"Bjornsson","year":"1996","journal-title":"Am J Pathol"},{"key":"R58-15-20210128","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1440-1827.2008.02322.x","article-title":"Epithelioid angiomyolipoma of the kidney.","volume":"59","author":"Kato","year":"2009","journal-title":"Pathol Int"},{"key":"R59-15-20210128","doi-asserted-by":"crossref","first-page":"e23379","DOI":"10.1371\/journal.pone.0023379","article-title":"Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and vegf- d levels decrease.","volume":"6","author":"Dabora","year":"2011","journal-title":"PLoS One"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e328351c646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T21:20:47Z","timestamp":1713561647000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201205000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e328351c646","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}